Page last updated: 2024-09-03

clofarabine and Cancer, Second Primary

clofarabine has been researched along with Cancer, Second Primary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC	1

Trials

1 trial(s) available for clofarabine and Cancer, Second Primary

Article	Year
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone marrow transplantation, 2022, Volume: 57, Issue:8 Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine	2022

Article

Year

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.

Bone marrow transplantation, 2022, Volume: 57, Issue:8

Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine

2022